Navigation Links
Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
Date:3/18/2009

SAN FRANCISCO, March 18 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a leading company in the development of novel therapeutics for heart failure patients, today announced that, pursuant to Nasdaq Marketplace Rule 4350(b)(1)(B), its audited financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K, filed on March 12, 2009, contained a going concern qualification from its independent registered public accounting firm, Hays & Company LLP.

This announcement is required by Nasdaq Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of receipt of an audit opinion containing a going concern qualification. This announcement does not represent any change or amendment to the company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2008.

2009 Objectives

Nile is focused on very specific clinical and corporate objectives:

  • To complete the dosing of a 30 patient, placebo-controlled Phase 2b study in the 3rd quarter of 2009. This study is designed to provide additional clinical evidence that CD-NP enhances renal function. This finding would favorably differentiate CD-NP from other acute heart failure therapies.
  • Through financing, partnering or other strategic alternative, secure the resources necessary to continue development activities beyond the 30 patient Phase 2b study.
  • To start enrollment into the 330 patient double-blind, placebo-controlled Phase 2b acute heart failure Proof of Concept study.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at the Needham Cancer Therapeutics Conference
2. Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... customers across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ... and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... Bedford, NH (PRWEB) , ... July 30, 2015 ... ... efficiency homogenizer for advanced fluid applications and designed for continuous operation up to ... clean-in-place and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ ...
(Date:7/29/2015)... / Japan (Q2 2015: +14% CER / 20% of ... growth in China , as well as solid contributions from ... Europe / Middle East / ... gains in Germany , Turkey and ... / 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across ...
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... COLUMBIA, Md., Dec. 13 Martek Biosciences,Corporation announced ... DHA and,ARA license and supply agreement for infant ... Pharmaceutical. Under the terms of the,agreement, Martek will ... IlDong,Foodis infant formula products in South Korea., ...
... the US Oncology Adjuvant Trial 9735 at 2007 ... and Cyclophosphamide Improved Overall ... Dec. 13 Results presented at the,30th annual ... for,women with early stage breast cancer who have ...
... diseases for this collaboration are Diffuse Large Cell Lymphoma, Transformed Follicular Lymphoma, and Chronic ... ... cancers in 2007 in ... US alone(1), -- MicroRNAs hold significant potential as highly sensitive and specific ...
Cached Biology Technology:Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea 2Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 2Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 3Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 4Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 5
(Date:6/25/2015)... 25, 2015  Imagine a tool specifically designed to ... happier life. That,s exactly what USANA,s True Health ... cutting-edge, portable health program provides a personalized approached to ... improve your lifestyle and nutrition. At ... Wednesday night, USANA,s THA was honored with the Industry ...
(Date:6/24/2015)... June 24, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of ...
(Date:6/24/2015)... Calif. , June 24, 2015  Synaptics ... of human interface solutions, today announced that Sharp ... to provide secure authentication for its latest flagship ... reached more than 200 million shipments of its ... Sharp reinforces Synaptics, strength, scalability and leadership in ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... will address the 31st annual Western Apicultural Society (WAS) ... The main conference sessions will take place in the ... Creek Road. "The conference provides an ... and to interact with professionals," said president Eric Mussen ...
... natural climate archives. For the temperate latitudes it ... depend mainly on temperature and precipitation. In the ... correlation is not so evident. Now scientists of the ... of the Australian National University have been able to ...
... What dog owner has not come home to a broken ... around the house? By ingeniously setting up conditions where the ... committed an offense, Alexandra Horowitz, Assistant Professor from Barnard College ... in dogs in the recently published "Canine Behaviour and Cognition" ...
Cached Biology News:'Honey bee health' of concern at Western Apicultural Society conference 2'Honey bee health' of concern at Western Apicultural Society conference 3Australia's climate: Drought and flooding in annual rings of tropical trees 2What really prompts the dog's 'guilty look' 2
... BODIPY FL ATP-Gamma-S binds to ATP-binding ... the BODIPY FL fluorophore was linked ... addition to its potential use for ... thioether is an important new substrate ...
... Using information-rich MSn data, the patent-pending ... multiple levels of fragmentation, isotope pattern ... to accurately determine the correct formula ... approaches for deducing empirical formulae from ...
... peptide synthesis with a wide variety of purity ... research needs. Purity: IG(>50%), >70%, ... Sequence Length: Up to 120 ... C-amidation, phosphorylation, D-amino acids, MAPs, KLH/BSA conjugation, and ...
... pyruvate, 50 mg/L streptomycin sulfate, 100 mg/L ... and magnesium chloride. The use of a ... is generally attributed to early workers in ... a solution of inorganic salts designed to ...
Biology Products: